Canada Markets open in 5 hrs 2 mins

NeutriSci Provides Update on Patent Pending Technology

VANCOUVER, British Columbia, June 04, 2018 (GLOBE NEWSWIRE) -- NeutriSci International Inc. ("NeutriSci") (NU.V) (NRXCF) (1N9.F) the innovator and pioneer behind neuenergy®, is pleased to announce advancements with its patent pending  technology, trade named “Cryolisation”. 

The Cryolisation process is used to prepare oral dosage forms comprising cannabinoid and stilbenoid compounds which improve the dissolution rate and bioavailability of cannabinoid compounds. 

Preliminary research data indicate that cannabinoid and stilbenoid formulations prepared using the Cryolisation process increase absorption rates of cannabinoid compounds 4 – 5 times over consumption of cannabinoid compounds alone. The tested formulations appear to increase the amount of active ingredient the body can absorb while simultaneously increasing the rate of absorption with THC and CBD detected in the bloodstream of subjects within 10 minutes of initial consumption.  NeutriSci’s Cryolisation technology may provide an opportunity for manufacturers of cannabinoid-infused products to use less active ingredient while still achieving the desired results, thus lowering cost of manufacturing while increasing profits.  

As previously announced, NeutriSci has filed a United States provisional patent application (United States Provisional Patent No. 62/628,735; Compositions Comprising Co-crystals of Stilbenoids and Cannabinoids) relating to compositions comprising pterostilbene and other stilbenoids in formulations which improve the dissolution rate and bioavailability of cannabinoid compounds. 

NeutriSci’s CEO, Glen Rehman stated, “We have spent a great deal of time and resources positioning ourselves to be ready for the international demand for Cryolisation technology.  Producers and manufacturers from around the globe have been inquiring about possible partnership opportunities; due to the potential of the Cryolisation technology and the popularity of the form factor of our products currently in development.”

On Behalf of the Board of Directors of

NEUTRISCI INTERNATIONAL INC.
Glen Rehman
CEO
NeutriSci International Inc.
Tel: (403) 264-6320
Email: grehman@neutrisci.com

About NeutriSci International Inc.

NeutriSci specializes in the innovation, production and formulation of nutraceutical products. Established in 2009, NeutriSci’s is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for neuenergy®, the Company’s natural energy and focus supplement that has at its core, the beneficial effects of blueberries. 

Neuenergy® contains a unique patented combination of blueberry extract (pterostilbene) and naturally derived caffeine, and is a revolutionary energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash associated with typical energy products. To find out more about neuenergy®, please visit www.getneuenergy.com

For more information, please visit: www.neutrisci.com

NEITHER THE TSX VENTURE EXCHANGE, THE CANADIAN SECURITIES EXCHANGE NOR OTC MARKETS GROUP INC., NOR THEIR REGULATIONS SERVICES PROVIDERS HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. There is no certainty that any of these events will occur.  Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulation S under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.

Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

Statements in this press release have not been evaluated by the Food and Drug Administration.  Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.

Contact:

Glen Rehman
CEO
403-264-6320
Grehman@neutrisci.com